19 June 2019 Comment
According to the British Skin Foundation, hidradenitis suppurativa is a long term, recurrent and painful disease in which there is inflammation (redness, tenderness and swelling) in areas of skin containing...
17 June 2019 News
Johnson & Johnson subsidiary Janssen has announced that Tremfya (guselkumab) reached its primary endpoint in the Phase III DISCOVER one and two studies, where it is being investigated for adults...
10 June 2019 Analysis
Diabetes UK use its annual Diabetes Week to raise awareness, as well as funds for, among other things, crucial research into new treatments for diabetes. One largely neglected therapeutic approach...
31 May 2019 Comment
The goal of maternal immunisation is to induce a de novo antibody response in the pregnant mother that can then be transmitted to the infant through the placenta.
29 May 2019 Comment
With the market becoming flooded with multiple biologics in inflammatory bowel disease, it will be crucial for Eli Lilly to strategically position its only therapy in this indication.
22 May 2019 Comment
The pediatric pneumococcal vaccine market is exceptionally lucrative, with PCV13 achieving global sales of $5.8 billion in 2018; therefore Pfizer stands to lose substantial income if Merck's V114 can garner...
17 May 2019 Comment
GlobalData believes that Skyrizi’s strong results from the four Phase III trials demonstrate the drug can be a strong contender in the highly competitive psoriasis market.
14 May 2019 Analysis
The theme of this year’s Mental Health Awareness Week is the connection between body image and mental health. There is an established two-way link between mental health conditions and psoriasis;...
23 April 2019 News
Global pharmaceutical company Eli Lilly has announced top line results for Taltz (ixekizumab) in non-radiographic axial spondyloarthritis (nr-axSpA).